Patents by Inventor Fritz Blatter

Fritz Blatter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11185545
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: November 30, 2021
    Assignee: Merck Patent GmbH
    Inventors: Rudolf Moser, Viola Groehn, Fritz Blatter, Martin Szelagiewicz, Ruth Boehni Stamm, Markus Ruettimann, Giuseppe Lapadula
  • Patent number: 11129820
    Abstract: The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: September 28, 2021
    Assignee: Vifor (International) AG
    Inventors: Collin D. Morris, Fritz Blatter, Giuseppe Lapadula, Stefan Reim, Michael Burgert, Erik Philipp
  • Publication number: 20210283136
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 16, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Publication number: 20210277006
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 9, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Publication number: 20210275533
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 9, 2021
    Applicant: Merck Patent GmbH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Publication number: 20210269444
    Abstract: The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 2, 2021
    Applicant: Merck Patent GmbH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Publication number: 20210220366
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: July 22, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Patent number: 11066408
    Abstract: The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the sodium is from 1:0.5 to 1:1.5 and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the organic base is 1:0.5 to 1:1.5 and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Rudolf Moser, Viola Groehn, Fritz Blatter, Martin Szelagiewicz, Ruth Boehni Stamm, Markus Ruettimann, Giuseppe Lapadula
  • Patent number: 11059829
    Abstract: In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: July 13, 2021
    Assignee: Acerta Pharma B.V.
    Inventors: Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts
  • Publication number: 20210107902
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 15, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Fritz BLATTER, Martin SZELAGIEWICZ, Ruth BOEHNI STAMM, Markus RUETTIMANN
  • Publication number: 20210002227
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 7, 2021
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Publication number: 20200361933
    Abstract: Salts, hydrates and solvates of Compound I and methods of making and using the same and related dosage forms thereof are disclosed.
    Type: Application
    Filed: February 1, 2019
    Publication date: November 19, 2020
    Inventors: Karthik Nagapudi, Yuan Liu, Shuai Wang, Wei Zhang, Fritz Blatter, Srikonda Sastry, Manshiu Leung, Ramachandran Radhakrishnan, Rajendra S. Tandale, Ludwig Pilsl, Roland Müller, Markus Frieser, Christine Czauderna, Lawrence Emerson Fisher
  • Publication number: 20200255437
    Abstract: In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Inventors: Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts
  • Publication number: 20200148644
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: January 13, 2020
    Publication date: May 14, 2020
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Patent number: 10640509
    Abstract: In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: May 5, 2020
    Assignee: Acerta Pharma B.V.
    Inventors: Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts
  • Publication number: 20200113885
    Abstract: The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.
    Type: Application
    Filed: April 18, 2018
    Publication date: April 16, 2020
    Inventors: Collin D. Morris, Fritz Blatter, Giuseppe Lapadula, Stefan Reim, Michael Burgert, Erik Philipp
  • Publication number: 20200039982
    Abstract: The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the sodium is from 1:0.5 to 1:1.5 and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the organic base is 1:0.5 to 1:1.5 and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.
    Type: Application
    Filed: March 28, 2018
    Publication date: February 6, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Fritz BLATTER, Martin SZELAGIEWICZ, Ruth BOEHNI STAMM, Markus RUETTIMANN, Giuseppe LAPADULA
  • Publication number: 20200030333
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.
    Type: Application
    Filed: March 28, 2018
    Publication date: January 30, 2020
    Applicant: Merck Patent GmbH
    Inventors: Rudolf MOSER, Viola GROEHN, Fritz BLATTER, Martin SZELAGIEWICZ, Ruth BOEHNI STAMM, Markus RUETTIMANN, Giuseppe LAPADULA
  • Publication number: 20190337949
    Abstract: In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
    Type: Application
    Filed: November 1, 2018
    Publication date: November 7, 2019
    Inventors: Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts
  • Publication number: 20190256469
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: May 1, 2019
    Publication date: August 22, 2019
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening